登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C26H28ClNO · C6H8O7
化学文摘社编号:
分子量:
598.08
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
form
powder
InChI key
IWEQQRMGNVVKQW-OQKDUQJOSA-N
SMILES string
OC(=O)CC(O)(CC(O)=O)C(O)=O.CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c2ccccc2)\c3ccccc3
InChI
1S/C26H28ClNO.C6H8O7/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-16H,17-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
assay
≥98% (HPLC)
storage condition
desiccated
color
white to off-white
solubility
DMSO: >10 mg/mL
storage temp.
2-8°C
Quality Level
Gene Information
human ... ESR1(2099), ESR2(2100)
General description
Toremifene is a triphenylethylene derivative. It exhibits antitumor and antiestrogen effects. Toremifene has estrogen-agonist effects on blood lipids and endometrium.
Application
Toremifene citrate salt has been used:
- in cell-based ELISA
- as a positive control to detect its antiviral activity against Ebola virus (EBOV)
- to treat MCF7 and T47D breast cancer cell lines
Biochem/physiol Actions
Toremifene citrate is an oral selective estrogen receptor modulator (SERM). It is used in advanced (metastatic) breast cancer and being evaluated for prevention of prostate cancer. Toremifene citrate is known to increase bone mineral density in prostate cancer patients undergoing androgen deprivation therapy†.
Features and Benefits
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Preparation Note
Toremifene citrate salt is soluble in DMSO at a concentration that is greater than 10 mg/ml.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Dam. 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Lack of effect of lamivudine on Ebola virus replication
Hensley LE, et al.
Emerging Infectious Diseases, 21(3), 550-550 (2015)
Hideaki Ogata et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(6), 749-753 (2013-07-19)
Third-generation aromatase inhibitors(AIs)are now common in adjuvant hormone therapy for breast cancer in postmenopausal women. However, a suitable treatment has yet to be established for patients who develop cancer recurrence during or after adjuvant AI therapy. This prospective study evaluated
L Kangas et al.
Cancer chemotherapy and pharmacology, 17(2), 109-113 (1986-01-01)
The antitumor effects of a new antiestrogen, Fc-1157a have been studied in vitro and in vivo. In vitro the effect of Fc-1157a was comparable to that of tamoxifen. The effect was dose-dependent, and at concentrations higher than 10(-6) mol/1 Fc-1157a
Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance.
DeGregorio MW, et al.
Journal of Clinical Oncology, 7(9), 1359-1364 (1989)
Prostate cancer and prostatic intraepithelial neoplasia: true, true, and unrelated?
Ian M Thompson et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(5), 515-516 (2013-01-09)
商品
We offers many products related to Nuclear Receptors (Steroids) for your research needs.
我们可提供多种核受体(类固醇)相关产品,满足您的各类研究需求。
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持

